UCSF Health Cancer Experts Featured at Premier Cancer Meeting

Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education. The theme this year is Partnering With Patients: The Cornerstone of Cancer Care and Research. More than 30,000 people are expected to attend the meeting taking place in Chicago and online June 2-6, 2023.

Personalizing Prostate Cancer Screening May Improve the Accuracy of Detection

The accuracy of prostate-specific antigen (PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, according to a multi-center study led by UC San Francisco and Stanford University.

ASCO and Memorial Sloan Kettering Honor Ashworth for Transformative Contributions

Alan Ashworth, PhD, FRS, president of the UCSF Helen Diller Family Comprehensive Cancer Center and senior vice president for cancer services at UCSF Health, has received two prestigious national awards for his transformative research accomplishments and work developing PARP inhibitors for cancer.

USPSTF’s Proposed Breast Cancer Screening Guidelines

USPSTF’s Proposed Breast Cancer Screening Guidelines prompt comments from UCSF Breast Imaging faculty Bonnie Joe, MD, PhD, and Kimberly Ray, MD.

Scientists Discover a Deadly Brain Cancer’s Hidden Weakness

Common and Cheap Epilepsy Drug Stops Tumor Growth in Mice

Woman receiving chemotherapy in a clinic

Transgender Women Benefit from Prostate Cancer Screenings

Study Shows Risk of Cancer Even After Gender-Affirming Surgery

UCSF Hospitals Earn ‘A’ for Patient Safety from Leapfrog Group

UCSF Health hospitals at Mission Bay and Parnassus Heights earned an “A” Hospital Safety Grade from The Leapfrog Group for spring 2023 – a national recognition of excellence for protecting patients from preventable harm and errors.

UCSF is First in California to Provide Drug-Gene Testing

Beginning May 9, UC San Francisco will be the first hospital in California, and one of only a few nationwide, to offer pharmacogenetic testing. The test will provide critical clues about a patient’s unique genetic makeup, enabling pharmacists to tailor medications and dosages accordingly.

A peek inside the infusion center at the Bakar Precision Cancer Medicine Building at the UCSF Mission Bay campus

UCSF Improves Care Options for Metastatic Gastrointestinal Cancer

UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.

CAB Co-Leaders Roxanna Bautista and Lisa Tealer: The Deep Work of Community Engagement

Earlier this year, Roxanna Bautista and Lisa Tealer were appointed co-leaders of the Cancer Center’s Community Advisory Board (CAB). In this Q & A, Bautista and Tealer discuss their community advocacy work and the CAB’s important role as a partner to the Cancer Center.

Eleven Cancer Research Projects Funded in Fall 2022 RAP Cycle

Funded by various agencies across UCSF, the awards span a range of topics from targeting cell growth in pancreatic cancer to predicting head and neck radiotherapy toxicities to evaluating a digital health intervention in breast cancer patients.

New Theranostic Approach Targets Prostate Cancer

Drs. Anil Bidkar, Robert Flavell, and Bin Liu along with other co-authors have recently published a paper on a therapeutic strategy to address the limitations of current PSMA-directed theranostic agents for prostate cancer.

This image shows various types of immune cells in the lymph node, each colored based on its cell type. Image by Spitzer Lab

Can Lymph Nodes Boost the Success of Cancer Immunotherapy?

Cancer treatment routinely involves taking out lymph nodes near the tumor in case they contain metastatic cancer cells. But new findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes shows that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes.